Normal view MARC view ISBD view

2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations

In Journal of Clinical and Experimental Hepatology
By: Kumar A.
Contributor(s): Acharya SK [Corresponding Author] | Singh SP | Arora A | Dhiman RK | Aggarwal R | Anand AC | Bhangui P | Chawla YK | Gupta SD | Dixit VK | Duseja A | Kalra N | Kar P | Kulkarni SS | Kumar R | Kumar M | Madhavan R | Prasad VGM | Mukund A | Nagra A | Panda D | Paul SB | Rao PN | Rela M | Sahu MK | Saraswat VA | Shah SR | Shalimar | Sharma P | Taneja S | Wadhawan M | The INASL Task-Force on Hepatocellular Carcinoma.
Material type: materialTypeLabelArticlePublisher: 2019Description: .Subject(s): Liver cancer | Transplant | RFA | TACE | Targeted therapy In: Journal of Clinical and Experimental Hepatology Vol. 10, no. 1, p. 43-80.Summary: Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management of HCC in India and neighboring countries. However, since 2014, many new developments have taken place in the field of HCC diagnosis and management, hence INASL endeavored to update its 2014 consensus guidelines. A new Task Force on HCC was constituted that reviewed the previous guidelines as well as the recent developments in various aspects of HCC that needed to be incorporated in the new guidelines. A 2-day round table discussion was held on 5th and 6th May 2018 at Puri, Odisha, to discuss, debate, and finalize the revised consensus statements. Each statement of the guideline was graded according to the Grading of Recommendations Assessment Development and Evaluation system with minor modifications. We present here the 2019 Update of INASL Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri-2 Recommendations.
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR19779

Address for Correponding Author: subratacharya@gmail.com

Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management of HCC in India and neighboring countries. However, since 2014, many new developments have taken place in the field of HCC diagnosis and management, hence INASL endeavored to update its 2014 consensus guidelines. A new Task Force on HCC was constituted that reviewed the previous guidelines as well as the recent developments in various aspects of HCC that needed to be incorporated in the new guidelines. A 2-day round table discussion was held on 5th and 6th May 2018 at Puri, Odisha, to discuss, debate, and finalize the revised consensus statements. Each statement of the guideline was graded according to the Grading of Recommendations Assessment Development and Evaluation system with minor modifications. We present here the 2019 Update of INASL Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri-2 Recommendations.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha